Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
NCT03574597
Completed
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/06/2024
Locations: Central Alabama Research, Birmingham, Alabama +832 locations
Conditions: Overweight, Obesity
Register for Updates
Mechanisms of Semaglutide Therapy in Heart Failure Patients
NCT06541509
Recruiting
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells. Their stimulation increases insulin and somatostatin secretion, and decreases glucagon secretion. In addition, GLP-1 receptor agonists appear to have multiple extrapancreatic actions, which remain poorly defined. In large clinical trials, semaglutide improved the outcomes in obese patients, patie... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
08/05/2024
Locations: Greenstone Biosciences, Palo Alto, California +2 locations
Conditions: Heart Failure, Obesity
Register for Updates
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
NCT05579977
Terminated
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Ry... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/09/2024
Locations: Trinity Clinical Research, Centreville, Alabama +89 locations
Conditions: Diabetes Mellitus, Obesity
Register for Updates
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
NCT05035095
Completed
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight. Participants will either get semaglutide tablets (new medicine) or placebo tablets ('dummy' medicine that looks like semaglutide but has no effect on the body). For a fair comparison, people are divided into two groups at random by a computer. This process is called randomisation. Sem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +50 locations
Conditions: Obesity, Overweight
Register for Updates
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
NCT04741074
Terminated
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Geisinger Medical Center, Danville, Pennsylvania +1 locations
Conditions: CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Register for Updates
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
NCT03919929
Active Not Recruiting
Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.
Gender:
FEMALE
Ages:
Between 12 years and 21 years
Trial Updated:
01/25/2024
Locations: University of Colorado Anshutz Medical Campus/Children's Hospital Colorado, Aurora, Colorado
Conditions: PCOS, Adolescent Obesity, NAFLD
Register for Updates
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
NCT04102189
Completed
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy" medicine. The teenagers in the study and their parents will also have talks with study staff about healthy food choices, how to be more physically active and what they can do to help the teenagers lose weight. The teenagers will either get semaglutide or "dummy" medicine - wh... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/29/2023
Locations: Novo Nordisk Investigational Site, Meridian, Idaho +36 locations
Conditions: Overweight, Obesity
Register for Updates
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03693430
Completed
This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine. In addition to taking the medicine, participants will also have talks with study staff about healthy food choices, how the participant can be more physically active and what participants can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/05/2023
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +40 locations
Conditions: Overweight, Obesity
Register for Updates
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
NCT04074161
Completed
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years. This is to compare the effect on body weight in people taking semaglutide once a week or people taking liraglutide once every day. Participants will either get semaglutide, liraglutide or "dummy" medicine. Which treatment is decided by chance. Participants who receive semaglutide or semaglutide "dummy" medicine will need to take 1 injection once a week. Participants w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2023
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +18 locations
Conditions: Overweight, Obesity
Register for Updates
Once Weekly GLP-1 in Persons With Spinal Cord Injury
NCT03292315
Completed
Chronic spinal cord injury (SCI) results in adverse soft tissue body composition changes and an extremely sedentary lifestyle. These abrupt changes often lead to a high prevalence of cardiometabolic diseases, such as impaired glucose tolerance/diabetes mellitus and dyslipidemia, conditions which predispose those with SCI to an increased risk for cardiovascular disease compared to the general population. Due to paralysis and wheel chair dependence, maintaining an adequate level of physical activi... Read More
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
03/10/2023
Locations: Kessler Institute for Rehabilitation, West Orange, New Jersey
Conditions: Spinal Cord Injuries, Insulin Resistance, Pre Diabetes, Obesity
Register for Updates
Semaglutide to Reduce Atrial Fibrillation Burden
NCT05209165
Suspended
Atrial fibrillation (AF) is the most common arrhythmia worldwide. AF is associated with obesity and the co-morbidities of obesity, including hypertension and obstructive sleep apnea (OSA) which increase left atrial (LA) size and decrease LA function. Semaglutide, a Glucagon-like peptide receptor 1 agonist (GLP-1 RA), is currently approved by the Food and Drug Administration for weight loss for individuals with and without diabetes. The effects of pharmacologic weight loss with Semaglutide on AF... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: Veterans Affairs Medical Center San Francisco, San Francisco, California
Conditions: Atrial Fibrillation, Obesity, Overweight
Register for Updates
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03548987
Completed
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what a participant can do to lose weight. The participant will get semaglutide for the first 20 weeks. Then the partic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2022
Locations: Novo Nordisk Investigational Site, Anniston, Alabama +71 locations
Conditions: Metabolism and Nutrition Disorder, Obesity
Register for Updates